Blog | HemaCare

STAT5 Proteins May Play a Critical Role in Effective Anti-Tumor Immune Response

Jun 29, 2021 10:10:00 AM / by Stacy Matthews Branch, DVM, PhD

AdobeStock_294467091 (1)-1A study has shown that cancer patients’ white blood cells were genetically engineered to enable T-cells to identify and destroy the cancer cells.

Chimeric antigen receptor (CAR) T-cells are immune cells that have been genetically engineered to generate a T-cell receptor capable of targeting specific cancer cells. A patient’s own T cells are collected, modified, then infused back into the patient. Although very promising results and successes have been noted for the application of CAR-T cell therapy for blood cancers, it is not without significant challenges to overcome. Among the challenges are patients that do not respond to the therapy, relapses, limited CAR-T cell life-span, rapid loss of anti-cancer function, and low efficacy against solid tumors.

Researchers from the Georgia Cancer Center of Augusta University have conducted a study that shows that CAR-T cells can have longer and more effective anti-cancer activity with the addition of an active signal transducer, activator of transcription 5 (STAT5), in CAR T cells. STAT5 is a signaling molecule that is essential for the development of T cells and the differentiation of helper T cells. The study consisted of the adoptive transfer of STAT5-transduced CAR-T cells into mice experimentally inoculated with tumor cells.

The researchers observed that active mouse STAT5 in the CAR-T cells enhanced expansion of T cells, longer CAR-T cell survival, the capacity to enter tumor cells, and cytotoxic T cell anti-tumor activity. Overall, the research results demonstrated that the addition of STAT5 to CAR-T cells provided improved anti-cancer outcomes in mice by promoting continued T-cell survival and activity in the body after killing cancer cells, a feature that can help reduce cancer relapse.

Further research is necessary to see if the observations of the mouse study holds true in humans. The safety of STAT5-enhanced CAR-T cells also remains to be determined. Thus far, STAT5 appears to be a beneficial component of CAR-T cell development that can provide the factors needed to overcome the current CAR-T cell therapy challenges by providing expanded, efficacious, and safe use as anti-cancer chemotherapy.

At HemaCare, we offer top quality cellular products for the advancement of medicine. If you would like to learn more about our products, contact us or visit us online.

References:

Emily Henderson, B. (2020). Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity. Retrieved 8 January 2021, from https://www.news-medical.net/news/20201214/Study-shows-how-STAT5-optimizes-function-of-CD42b-T-cells-to-drive-antitumor-immunity.aspx

Topics: Cancer, CAR-T

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts